Transcription Factor 7-like 2 (TCF7L2) Polymorphism Was Associated with Worse Survival in Three Independent Cohorts from the USA, Austria, and Japan Rita.

Slides:

Advertisements

Similar presentations

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

Advertisements

Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.

Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in HER2- Positive, First-Line Metastatic Breast Cancer (MBC) Baselga.

Mizutomo Azuma 1, Michael M. Shi 2, Christian J. Jacques 2, Carl Barrett 2, Kathleen D. Danenberg 3, Syma Iqbal 1, Anthony El-Khoueiry 1, Dongyun Yang.

Introduction Materials and Methods Results Conclusions CD133 Polymorphisms are associated with clinical outcome in metastatic colorectal cancer (mCRC)

Introduction Patients and Methods Results Conclusion Wnt signaling is essential for embryonic development, stem cells and tissue regeneration. Colorectal.

PREOPERATIVE PLASMA CONCENTRATION OF MMP-9/TIMP-1 COMPLEXES IS NOT ASSOCIATED WITH DISEASE OUTCOME IN PRIMARY BREAST CANCER (N=483) Anne-Sofie Schrohl.

KRAS is mutated in about 40% of colorectal cancers; it is the only validated predictive marker used in patients with metastatic CRC 1. It is also a negative.

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.

Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005) 1 Concordance of HER2 Central Assessment.

References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.

Novel Colon Cancer Tumor Suppressor Gene, Defensin-β1, Predicts Recurrence in Patients with Stage II and III Colon Cancer. Melissa J. LaBonte 1/2, Pierre.

A 14-gene prognosis signature predicts metastasis risk in node-negative, estrogen receptor-positive, Tamoxifen-treated breast cancer in different ethnogeographic.

10 Minutes Talk 吳華席 Hua-Hsi Wu, MD OB/GYN, VGH-TPE Sep 08, 2008.

Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.

Insert Program or Hospital Logo Introduction Melanoma is notoriously resistant to chemotherapy. While surgical resection and adjuvant chemotherapy can.

Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.

A Quantitative Multi-Gene RT-PCR Assay for Prediction of Recurrence in Stage II Colon Cancer (CC): Selection of the Genes in 4 Large Studies and Results.

Clinical Trials Evaluating the Role of Sentinel Node Resection in Patients with Early-Stage Breast Cancer Krag DN et al. Proc ASCO 2010;Abstract LBA505.

A Micro RNA Polymorphism (MiRSNP) in 3’UTR of K-ras gene was associated with clinical outcome in mCRC patients treated with either single agent cetuximab.

Mizutomo Azuma 1, Dongyun Yang 2, Marinella Carpanu 3, Ellen Hollywood 3, Michael Lue-Yat 3, Wu Zhang 1, Kathleen D. Danenberg 4, Peter V. Danenberg 5,

Huidi Liu, M.D. & Ph.D Genomics Research Centre Harbin Medical University, China Reduced expression of SOX7 in ovarian cancer: a novel.

Prospective study of EGFR intron 1 CA tandem repeats as predictive factor of benefit from cetuximab and irinotecan Antoniotti C 1, 2, Loupakis F 3, Cremolini.

Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,

*University Hospital Gasthuisberg, Leuven, Belgium

ICAM-1, GRP-78 and NFkB gene polymorphisms associated with clinical outcome in patients with metastatic colorectal cancer treated with first line 5-FU.

Introduction Results Material and Methods Conclusions Genetic variants predict clinical outcome clinical outcome in patients (pts) with metastatic colorectal.

Cancer Stem Cell SNPs Have Opposite Prognostic Outcome in Patients with Gastric Cancer Among Asian and Western Countries Melissa J. LaBonte 1, Takeru Wakatsuki.

Gene Expression Signatures for Prognosis in NSCLC, Coupled with Signatures of Oncogenic Pathway Deregulation, Provide a Novel Approach for Selection of.

T Andre, E Quinaux, C Louvet, E Gamelin, O Bouche, E Achille, P Piedbois, N Tubiana-Mathieu, M Buyse and A de Gramont. Updated results at 6 year of the.

Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center – Knoxville Departments of Pathology, Surgery, and Medicine BREAST.

Germline polymorphisms in the CD44 gene are associated with clinical outcome in localized gastric adenocarcinoma. Thomas Winder, M.D. University of Southern.

First Author: Radu Cristina Co-Authors: Stefan Anda Tripon Florin Crauciuc George Coordinators: Banescu Claudia, MD Demian Smaranda, MD The importance.

Effect of 21-Gene Reverse- Transcriptase Polymerase Chain Reaction Assay on Treatment Recommendations in Patients with Lymph Node-Positive and Estrogen.

Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU- leucovorin as 1st line chemotherapy for metastatic.

Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,

KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten.

Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.

Introduction Patients and Methods Results Conclusion Pericytes are a key component in the maturation of the VEGF driven tumor angiogenic process 1. Bevacizumab.

Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.

The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB Nadine A. Jackson, Charles S.

1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.

Introduction Patients and Methods Results Conclusion Table 1. Baseline characteristics of the 108 patients included in the biomarker analysis. Objectives.

IntroductionPatient baseline characteristics Conclusion The process of EGFR recycling is important mechanism of resistance of cetuximab in colorectal cancer.

S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.

Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,

Pharmacogenetic analysis in metastatic colorectal cancer (mCRC) patients treated with second-line irinotecan (IR)+/- cetuximab (CB): The EPIC experience.

Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer In association.

What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,

Association of Family History with Cancer Recurrence and Survival in Patients with Gastric Cancer Journal of Clinical Oncology : R2 Hwang.

Chips? SNPs? or PCR? What do we really want and what do we need? Heinz-Josef Lenz, MD Professor of Medicine Co-Director, Colorectal Center Co-Director,

ABSTRACT Purpose This retrospective review was conducted to determine if delay in the start of radiotherapy after conservative breast surgery had any detrimental.

ADVERSE PROGNOSTIC FACTORS IMPACTING SURVIVAL IN RESECTED INVASIVE, MUCINOUS CYSTADENOCARCINOMAS OF THE PANCREAS Stephen J. Ko 1, Michele M. Corsini 2,

Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.

Immunoscore Prognostic in Colon Cancer

Ulcerative Colitis (UC)-Associated Colorectal Cancer (CRC) Patients Who Receives Colorectal Surgery More Likely Receive Blood Transfusion Than Crohn’s.

TBCRC (the translational breast cancer research consortium) 005 Prospective study

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

VEGF and VEGFR1 Gene expression levels predict tumor recurrence in adjuvant colon cancer Yan Ning1, Georg Lurje1, Kathleen Danenberg2, Janine Cooc2, Dongyun.

Genetic variants of kinases suppressors of Ras (KSR)in KRAS-BRAF

A subgroup analysis of a large multicenter study

Human triple‐negative breast cancers (TNBC) express WNT10B, show active Wnt signalling and have high proliferation, and WNT10B has clinical relevance and.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: a meta-analysis of the CRYSTAL and OPUS studies according to KRAS.

Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous.

Treated with Neoadjuvant Therapy

KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab Marta Schirripa1, Fotios Loupakis1, Chiara Cremolini1, Dongyun.

Presentation transcript:

Transcription Factor 7-like 2 (TCF7L2) Polymorphism Was Associated with Worse Survival in Three Independent Cohorts from the USA, Austria, and Japan Rita El-Khoueiry 1, Takeru Wakatsuki 1, Yan Ning 1, Wu Zhang 1, Dongyun Yang 2, Mizutomo Azuma 3, Armin Gerger 5, Michael Stotz 5, Melissa J. LaBonte 1, Nico Volz 1, Sebastian Stintzing 1, Joseph E Li 1, Peter M Wilson 1, Wasaburo Koizumi 3, Masahiko Watanabe 4, Martin Maus 1, Afsaneh Barzi 1, Syma Iqbal 1, Anthony El-Khoueiry 1, and Heinz-Josef Lenz 1,2 1. Department of Medical Oncology, 2. Department of Preventive Medicine; University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 3. Department of Gastroenterology, 4 Department of Surgery; Kitasato University East Hospital 5. Division of Clinical Oncology, Medical University of Graz 369 patients with histopathologically-confirmed localized GC were enrolled (stage Ib-IV; TNM 6th), 169 patients from Japan, 137 patients from the USA, and 63 patients from Austria between 2002 and D2 lymphadenectomy based surgery were conducted in Japan and Austria, while D1 lymphadenectomy based surgery were conducted in the USA. Adjuvant fluoropyrimidine based chemotherapy was conducted in ~60% of patients. Genomic DNA was extracted from peripheral blood or formalin fixed paraffin embedded tumor tissue using the QIAmp kit. All samples were analyzed by means of PCR-based direct DNA- sequencing. The primary endpoint of this study was time to recurrence (TTR) in the USA cohort and disease-free survival (DFS) in the Japanese and Austrian cohorts. The secondary endpoint was overall survival (OS). To evaluate prognostic value of this polymorphism, endpoints were estimated using Kaplan-Meier method and compared by log-rank test. The level of significance was set to p < The Wnt/β-catenin signaling pathway controls cell proliferation, differentiation, and stem cell maintenance. Disruption of this pathway has been shown in the majority of colorectal (CRC) and gastric cancers (GC) (1-3). The TCF7L2 complex plays a critical role in this pathway. Interaction of TCF7L2 and β-catenin results in translocation to the nucleus and leads to up-regulation of target genes, including c-myc and cyclin D1. Previous reports have shown that the TCF7L2 polymorphism, rs C/T, is associated with risk of CRC and breast cancer (4, 5); however, so far, no data has been provided for the prognostic role of this polymorphism in GC. Therefore, we tested the hypothesis of whether this polymorphism could predict outcome in GC using three independent cohorts (USA, Austria and Japan) that were ethnically and etiologically different. Abstract ID: Results Conclusions Introduction Methods 4088 Patients characteristics in this study are shown in Table 1. In the USA cohort, TCF7L2 polymorphism (rs ) TT/CT showed a shorter TTR than CC (1.7 vs. 4.4 years, HR: %CI: , p=0.0053) (Figure 1). A similar trend was shown in the Austrian cohort, TT/CT showed a shorter DFS than CC (2.08 vs years, HR: 1.79 [95%CI: ], p=0.092) (Figure 2). Moreover, in the Japanese cohort, TT showed a shorter DFS than CT/CC (0.15 vs years, HR: 10.5 [95%CI: ], p=0.001) (Figure 3). These results were confirmed in the OS in the US and Japanese cohorts. TT/CT showed a shorter OS (3.3 vs. 5.5 years, HR: %CI: , p=0.0043) in the USA cohort. TT showed a shorter OS than CT/CC (0.22 vs years, HR: 15.2 [95%CI: ], p<0.001) in the Japanese cohort. The TCF7L2 polymorphism was associated with worse prognosis in terms of recurrence in patients with GC in three independent global cohorts. This polymorphism may be negative prognostic factor in GC regardless of ethnicity and etiology, suggesting the important role of Wnt/β-Catenin signaling in GC. References Figure 1: USA CohortFigure 2: Austrian Cohort Figure 3: Japanese Cohort Table 1:Patients characteristics of 3 cohorts JapaneseAustrianUSC Total number(%)Total number(%)Total number(%) Ethnicity Japanese169100Caucasian63100Caucasian6346 Hispanic others Median Age, yrs Median Age All68 (31-88)All66 (37-86)All64 (26-85) Gender Male Male3250.8Male Female6035.5Female3149.2Female Stage Ib2816.6Ib1219.4Ib128.8 II5331.4II2540.3II III6035.5III2540.3III IV2816.6IV T category N category ECOG PS NA NA NA Tumor Site Stomach Stomach4877.4Stomach GEJ31.8GEJ1422.6GEJ Tumor differentiation well/mode6840.2moderate711.1well/mode3727 poor poor5079.4poor Undifferentiated69.5 Lauren class. Diffuse Diffuse2760.0Diffuse Intestinal6840.2Intestinal1124.4Intestinal Mixed Mixed Type of chemo. S-1 based FU or cape. based FU/LV UFT169.5Taxan based23.25-FU/Oxali others63.6others34.85-FU, Cis, CPT none6035.5none4977.8none Radiation yes yes no169100no6095.2no4835 1) Powell SM, et al; Nature, 359: ) Fearon ER, et al; Cell, 61: )Oshima H, et al; Gastroenterology, 131: ) Slattely ML, et al; Cancer Epidemiol Biomarker Prev, 17: ) Naidu R, et al; Med Oncol, 29:2011. A B A B A B